A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease
Por:
C. GIMENEZ-GARZO, A. FIORILLO, M. BALLESTER-FERRE, J. GALLEGO, F. CASANOVA-FERRER, A. URIOS, S. BENLLOCH, D. MARTI-AGUADO, T. SAN-MIGUEL, J. TOSCA, M. RIOS, C. MONTON, L. DURBAN, D. ESCUDERO-GARCIA, L. APARICIO, V. FELIPO and C. MONTOLIU
Publicada:
1 jul 2021
Resumen:
Patients with nonalcoholic fatty liver disease (NAFLD) may show mild cognitive impairment (MCI). The neurological functions affected remain unclear. The aims were to: (1) Characterize the neuropsychological alterations in NAFLD patients; (2) assess the prevalence of impairment of neurological functions evaluated; (3) develop a new score for sensitive and rapid MCI detection in NAFLD; (4) assess differences in MCI features between patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); and (5) compare neuropsychological alterations in NAFLD patients with cirrhotic patients with MCI. Fifty-nine NAFLD patients and 53 controls performed psychometric tests assessing different neurological functions: PHES (Psychometric Hepatic Encephalopathy Score) battery, d2, Stroop, Oral SDMT (Symbol Digit Modalities Test), Digit Span, number-letter test, and bimanual and visual-motor coordination tests. NAFLD patients show impairment in attention, mental concentration, psychomotor speed, cognitive flexibility, inhibitory mental control, and working memory. We developed a new, rapid, and sensitive score based on the most affected parameters in NAFLD patients, unveiling that 32% of NAFLD show MCI. Prevalence was similar in NAFL (36%) or NASH (27%) patients, but lower in NAFLD than in cirrhosis (65%). MCI prevalence is significant in NAFLD patients. Psychometric testing is warranted in these patients to unveil MCI and take appropriate measures to reverse and prevent its progression.
Filiaciones:
:
Ctr Invest Principe Felipe, Neurobiol Lab, Valencia 46012, Spain
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
A. FIORILLO:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
M. BALLESTER-FERRE:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
Hosp Clin Valencia, Serv Med Digest, Valencia 46010, Spain
J. GALLEGO:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
F. CASANOVA-FERRER:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
:
Ctr Invest Principe Felipe, Neurobiol Lab, Valencia 46012, Spain
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
S. BENLLOCH:
Hosp Arnau Vilanova, Serv Digest, Valencia 46015, Spain
Inst Salud Carlos III, CIBERehd, Madrid 28029, Spain
D. MARTI-AGUADO:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
Hosp Clin Valencia, Serv Med Digest, Valencia 46010, Spain
T. SAN-MIGUEL:
Univ Valencia, Dept Patol, Valencia 46010, Spain
J. TOSCA:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
Hosp Clin Valencia, Serv Med Digest, Valencia 46010, Spain
M. RIOS:
Hosp Arnau Vilanova, Serv Digest, Valencia 46015, Spain
C. MONTON:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
Hosp Clin Valencia, Serv Med Digest, Valencia 46010, Spain
L. DURBAN:
Hosp Arnau Vilanova, Serv Digest, Valencia 46015, Spain
D. ESCUDERO-GARCIA:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
Hosp Clin Valencia, Serv Med Digest, Valencia 46010, Spain
Univ Valencia, Dept Med, Valencia 46010, Spain
L. APARICIO:
Univ Valencia, Dept Anat & Embriol, Valencia 46010, Spain
:
Ctr Invest Principe Felipe, Neurobiol Lab, Valencia 46012, Spain
:
INCLIVA, Inst Invest Sanitaria, Fdn Invest Hosp Clin, Valencia 46010, Spain
Univ Valencia, Dept Patol, Valencia 46010, Spain
Green Published, gold
|